TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Change in Resting-State Functional Connectivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Self-Attribution Task performance
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in Task-Based Activity during Self-Attribution Task
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Polysomnographic characteristics of sleep
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent of patients receiving counseling for drug-drug interactions
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: baby behavior and physiology
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Drug survival rate of secukinumab
Endpoint domain: Mortality/survival
Primary endpoint: Photography of the scar
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in serum 25-hydroxyvitamin D level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in The Unified Parkinson's Disease Rating Scale (UPDRS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Maximum Observed Plasma Concentration (Cmax) of Nemolizumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under Concentration-time Curve Extrapolated to Infinity (AUC0-inf) of Nemolizumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total number of internalizing problems
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: total fentanyl consumption
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Time to first occurrence of MOGAD relapse
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urinary phosphorus excretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Serum phosphorus and calcium levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: sound localization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Objective electroencephalography-based assessment (EEG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Relative change in UACR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Weight loss response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Time for body temperature to normalize
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: White blood cell characterization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Self-reported assessment of fatigue & associated variables
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Subjects' perceived digestive/bowel health
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Area Under the Plasma Concentration-Time Curve (AUC) of Risdiplam
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Steady-state Concentration (Css) of Risdiplam
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risdiplam Free Fraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of detection of PFO
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Participants with Adverse events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants with Clinically Significant Changes in 12-lead Electrocardiogram Parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Sleep treatment outcome
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Maximum tolerated dose (MTD) of iberdomide
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Variation in the angle of anteflexion of the uterus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Treatment success after 1 year of implant placement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: APT-CEST levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Guanidyl/APT ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants with Microvascular Obstruction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Shoulder pain and disability level
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: The Quality of Life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Compliance with treatment in the experimental arm
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Oxygenated hemoglobin (HbO) change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Symptomatic neuroma formation (sensation)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Symptomatic neuroma formation (pain)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Anti-DENV antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Annual number of flare-up of asthma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Breastfeeding attrition rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Optical Quality
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnostic accuracy of whole-body MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Respiratory Muscle Strength Measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Regional failure-free survival
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of spiking
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bubble Inclinometer for Active Knee Extension test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Image J software for Craniovertebral Angle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in regional lung ventilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Changes in Vital Signs Measurement: Systolic and Diastolic blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Rate of Participants with Post-surgery Complications
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Western Ontario Rotator Cuff (WORC)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Complete metabolic response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acceptable length of CHEC
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: CHEC's ease of use
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: CHEC's helpfulness in identifying caregivers' needs
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: CHEC's helpfulness in starting a conversation with health care providers
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Desire to continue use
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Incidence and severity of self-reported non-physical aggression
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence and severity of self-reported physical aggression
Endpoint domain: Adverse events/effects
Primary endpoint: Steady-state area under the concentration-time profile (AUC24)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Steady-state maximum observed concentration (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Steady-state time to reach maximum observed concentration (Tmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline of HADS anxiety scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change from baseline of HADS depression scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Reduction of heart rate alteration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reduction of oxygen saturation alteration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Reduction of respiratory rate alteration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Reduction of episodes of apnoea
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Curing effect of the suturation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Instrumental Activities of Daily Living (IADL) scale
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Incidence, nature and severity of AEs and SAEs
Endpoint domain: Adverse events/effects
Primary endpoint: Determination of the recommended Phase III dose (RP3D)
Endpoint domain: Resource use
Primary endpoint: Superiority of AZD0486 plus rituximab compared to Investigator's choice of SoC chemoimmunotherapy
Endpoint domain: Physiological/clinical
Primary endpoint: Changes in depression scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Changes in anxiety scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in facial wrinkles and fine lines
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in Joints Pain using VAS
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in hair growth on the scalp
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change from baseline pre-lab test rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative Atrial fibrillation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Participants with Primary Adverse Events (PAE's)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants with Acute Effectiveness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Preparing for Life as a (New) Survivor (PLANS) Scale Score: Part 1
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Preparing for Life as a (New) Survivor (PLANS) Scale Score: Part 2
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Changes in bariatric surgery nutrition-knowledge score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Completeness
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Understandability
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Remission of Arthritis and/or Rash
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean overall IDEEL-Symptom Bother score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Opioid prescribing reduction
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Proximal seal outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Gaze stability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Diagnostic value of IVCCI to detect post-induction hypotension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Diagnostic value of IVC : Ao index to detect post-induction hypotension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Measurement of aerobic capacity (endurance)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Measurement of anaerobic capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Treatment response by shear wave elastography
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of measured residual disease (MRD) negative complete remission (CR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fidelity to WISE Evidence-Based Practices
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Barriers to physical activity
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Quality of Life measured by EQ-5D-5L VAS
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: MRI motion artifact
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of relapses
Endpoint domain: Adverse events/effects
Primary endpoint: Repeated requests for correction of disorders
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Rate of complete occlusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Change in total vasomotor rhinitis symptom score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Shoulder pain numeric rating scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intermittent fasting compliance as measured by serum glucose laboratory testing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Intermittent fasting compliance as measured by ketone laboratory testing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Intermittent fasting compliance as measured by IGF-1 laboratory testing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Intermittent fasting compliance as measured by insulin laboratory testing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Intermittent fasting compliance as measured by self-reported assessment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Time to first recurrence of any atrial tachyarrhythmia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Horizontal bone width
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent Maintenance of Body Weight Reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Dynamic Strain in the Glabella Area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cell yield
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage cell viability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incisional Hernia Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Mean log10 Time to positivity (TTP) slope
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative proportion of participants with Grade 3 or higher adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Health-related Quality of Life - EQ-5D-3L/-Y
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: The Positive and Negative Affect Schedule
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: The Short Warwick-Edinburgh Mental Well-Being Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: therapeutical activity of Ozanimod
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of participants with normally completed pregnancies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Number of participants with maternal anemia of any severity in third trimester
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Mean and change in score of quality of life gravidarum (QoL-Grav) in first to third trimester
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Gene expression parameters before surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Strength of connectivity in brain network
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Systemic metabolome profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence rate of adverse drug reactions (ADRs)
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence rate of fatal adverse events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Time to GI-2 bowel function after surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Subjective upper limb function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Objective upper limb function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity for Detection of HPV 16, 18 and gene ACTB
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificity for Detection of HPV 16, 18 and gene ACTB
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall Accuracy - All Participants
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of participants with a ≥30% decrease in mean iPTH
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Cancer-related symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Distant Metastasis
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of radiation dermatitis grade 3+
Endpoint domain: Adverse events/effects
Primary endpoint: Frequency of sufficient Tidal volume generated by electromagentical stimulation of the phrenic nerve
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Cmax of HRS-5041
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-t of HRS-5041
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tmax of HRS-5041
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Treatment outcome at day 180
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUCn(6h-30d) of the ratio to baseline of clot burden
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of participants with composite of major and clinically relevant non-major (CRNM) bleeding events
Endpoint domain: Adverse events/effects
Primary endpoint: correlation of mpMRI and prostate biopsy pathology results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Time in Target Glucose Range (70-140 mg/dL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Endoscopic diagnosis rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Borderline Personality Disorder Severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Early treatment dropout rate
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Primary bleeding endpoint
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants Meeting ACR50 Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Incidence of severe adverse events during mitochondrial infusion
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of severe adverse vascular events immediately post-mitochondrial infusion
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of severe systemic adverse events associated with mitochondrial infusion
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of severe adverse events related to muscle biopsy
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum Tolerated Dose (MTD) of CAR T cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in QMG total score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PrEP Uptake: Self-report
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: PrEP Adherence: Visual analog scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HIV testing uptake: Self-report
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in GI - Gingival Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in PI - Plaque Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: International Hip Outcome Tool 12 (iHot-12)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Hip and Groin Outcome Score (HAGOS)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Hip Outcome Score (HOS) ADL
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Hip Outcome Score (HOS) Sport
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning